Fulgent Genetics, Inc.FLGTEarnings & Financial Report
Fulgent Genetics, Inc. is a molecular diagnostics technology firm that develops and offers genetic testing services including carrier screening, oncology testing, infectious disease detection, and hereditary condition analysis, serving clinical providers, pharma firms, research institutions and public health groups primarily in North America.
FLGT Q1 FY2026 Key Financial Metrics
Revenue
$71.1M
Gross Profit
$21.5M
Operating Profit
$15.0M
Net Profit
N/A
Gross Margin
30.2%
Operating Margin
21.1%
Net Margin
N/A
YoY Growth
-3.2%
EPS
$0.04
Fulgent Genetics, Inc. Q1 FY2026 Financial Summary
Fulgent Genetics, Inc. reported revenue of $71.1M (down 3.2% YoY) for Q1 FY2026, with a net profit of N/A (N/A margin). Cost of goods sold was $49.6M, operating expenses totaled $6.5M.
Key Financial Metrics
| Total Revenue | $71.1M |
|---|---|
| Net Profit | N/A |
| Gross Margin | 30.2% |
| Operating Margin | 21.1% |
| Report Period | Q1 FY2026 |
Fulgent Genetics, Inc. Annual Revenue by Year
Fulgent Genetics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $322.7M).
Fulgent Genetics, Inc. Quarterly Revenue & Net Profit History
Fulgent Genetics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $71.1M | -3.2% | N/A | N/A |
| Q4 FY2025 | $83.3M | +9.3% | $-23.4M | -28.1% |
| Q3 FY2025 | $84.1M | +17.2% | $-6.6M | -7.9% |
| Q2 FY2025 | $81.8M | +15.2% | $-19.0M | -23.2% |
| Q1 FY2025 | $73.5M | +13.9% | $-11.5M | -15.7% |
| Q4 FY2024 | $76.2M | +8.1% | $-5.9M | -7.7% |
| Q3 FY2024 | $71.7M | -15.3% | $-14.6M | -20.4% |
| Q2 FY2024 | $71.0M | +4.7% | $-8.7M | -12.3% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $71.0M | $71.7M | $76.2M | $73.5M | $81.8M | $84.1M | $83.3M | $71.1M |
| YoY Growth | 4.7% | -15.3% | 8.1% | 13.9% | 15.2% | 17.2% | 9.3% | -3.2% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.23B | $1.23B | $1.22B | $1.21B | $1.20B | $1.21B | $1.21B | $1.16B |
| Liabilities | $103.4M | $98.9M | $90.8M | $83.0M | $88.2M | $93.8M | $106.8M | N/A |
| Equity | $1.13B | $1.14B | $1.13B | $1.13B | $1.12B | $1.13B | $1.11B | N/A |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $4.3M | $-15.5M | $25.0M | $-4.4M | $-30.2M | $11.1M | $-78.1M |